Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 7/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614833 | 0.98 | PRKCI (0.41) | PRKCIHTR2CCETPPDE5AP2RY12 | |
| SCHEMBL1322247 | 0.93 | PRKCI (0.39) | PRKCIHTR2CCETPPDE5AP2RY12 | |
| SCHEMBL2614835 | 0.91 | PRKCI (0.41) | PRKCIHTR2CPDE5A | |
| SCHEMBL1320675 | 0.91 | PRKCI (0.41) | PRKCIHTR2CPDE5A | |
| SCHEMBL2614837 | 0.90 | PRKCI (0.40) | PRKCIHTR2CPDE5AP2RY12 | |
| SCHEMBL1320912 | 0.90 | PRKCI (0.50) | PRKCIHTR2C | |
| SCHEMBL1322420 | 0.90 | ALDH1A1 (0.40) | PRKCIHTR2CALDH1A1HPGDKDM4E | |
| SCHEMBL1322561 | 0.90 | PRKCI (0.41) | PRKCIHTR2CPDE5AP2RY12ALDH1A1 | |
| SCHEMBL2855292 | 0.90 | P2RY12 (0.41) | PRKCIHTR2CPDE5AP2RY12ALDH1A1 | |
| SCHEMBL13513554 | 0.89 | PRKCI (0.40) | PRKCIHTR2CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778804-B1 | SINGLE-COMPONENT SYSTEM BASED ON CO-REACTIVE LATEX, PREPARATION METHOD AND USE IN THE FIELD OF FORMOL-FREE COATINGS | ARKEMA FRANCE (FR) | 2010-01-20 | — | — | EP | claimed |
| EP-0875541-B1 | Single phase system based on coreactive latex resins | ATOFINA (FR) | 2003-09-10 | — | — | EP | claimed |
| EP-0875540-B1 | Single phase system based on coreactive latex resins | ATOFINA (FR) | 2002-11-13 | — | — | EP | claimed |
| EP-0875540-A1 | Single phase system based on coreactive latex resins | ELF ATOCHEM S.A. (FR) | 1998-11-04 | — | — | EP | claimed |
| EP-0875541-A1 | Single phase system based on coreactive latex resins | ELF ATOCHEM S.A. (FR) | 1998-11-04 | — | — | EP | claimed |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | CURACYTE DISCOVERY GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | CURACYTE DISCOVERY GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | CURACYTE DISCOVERY GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-8058285-B2 | Phosphodiesterase-4 (PDE-4) inhibitors; for treating bronchial asthma, COPD, rheumatoid arthritis (RA), osteoarthritis, cystic fibrosis, Guillain-Barresyndrome, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, allergic eczemas | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058285-B2 | Phosphodiesterase-4 (PDE-4) inhibitors; for treating bronchial asthma, COPD, rheumatoid arthritis (RA), osteoarthritis, cystic fibrosis, Guillain-Barresyndrome, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, allergic eczemas | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058285-B2 | Phosphodiesterase-4 (PDE-4) inhibitors; for treating bronchial asthma, COPD, rheumatoid arthritis (RA), osteoarthritis, cystic fibrosis, Guillain-Barresyndrome, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, allergic eczemas | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-1773840-B1 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3',2':4,5]FURO[3,2-D]-PYRIMIDINES FOR USE AS INHIBITORS OF PDA-4 AND/OR TNF-ALPHA RELEASE | MEDICINES CO LEIPZIG GMBH (DE) | 2010-01-20 | — | — | EP | disclosed |
| EP-1773840-A1 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3',2':4,5]FURO[3,2-D]-PYRIMIDINES FOR USE AS INHIBITORS OF PDA-4 AND/OR TNF-ALPHA RELEASE | Curacyte Discovery GmbH (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010567-A1 | SUBSTITUTED PYRIDO[3', 2': 4, 5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3', 2': 4, 5]FURO[3, 2, D]PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF$G(A) | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010567-A1 | SUBSTITUTED PYRIDO[3', 2': 4, 5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3', 2': 4, 5]FURO[3, 2, D]PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF$G(A) | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| EP-0875541-B1 | Single phase system based on coreactive latex resins | ATOFINA (FR) | 2003-09-10 | — | — | EP | disclosed |
| EP-0875540-B1 | Single phase system based on coreactive latex resins | ATOFINA (FR) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001054896-A2 | MULTILAYER COMPOSITE PRODUCT COMPRISING A PRESSURE-SENSITIVE AND TEMPERATURE-RESISTANT ADHESIVE POLYMER LAYER | ATOFINA (FR) | 2001-08-02 | — | — | WO | disclosed |
| EP-0875540-A1 | Single phase system based on coreactive latex resins | ELF ATOCHEM S.A. (FR) | 1998-11-04 | — | — | EP | disclosed |
| EP-0875541-A1 | Single phase system based on coreactive latex resins | ELF ATOCHEM S.A. (FR) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094987-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha | PDE4A, PDE4B, PDE3B | PRKCI 2308/4885HTR2C 1597/4885CETP 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.